Radiosensitivity of neuroendocrine cancer cells to 177Lu-DOTATATE and radiobiological implications for peptide radionuclide therapy

被引：0
|
作者：
Tamborino, G. [1 ,2 ]
Engbers, P. [1 ,2 ]
de Wolf, T. [1 ,2 ]
Reuvers, T. [1 ,2 ]
Konijnenberg, M. [1 ]
Nonnekens, J. [1 ,2 ]
机构：
[1] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands
[2] Erasmus MC, Dept Mol Genet, Rotterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-146
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [21] Targeted Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Alters Joints Inflammation
    Usmani, Sharjeel
    Rasheed, Rashid
    Ahmed, Najeeb
    Omar, Yehia
    Numani, Shah P.
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (02) : e102 - e104
  • [22] Establishing a clinical dosimetry protocol for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Bissell, S.
    Ross, E.
    McMeekin, H.
    Seal, E.
    Ogunwale, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S106 - S106
  • [23] Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Talole, Sanjay
    Prabhash, Kumar
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 428 - 435
  • [24] Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
    Pirisino, Riccardo
    Filippi, Luca
    D'Agostini, Antonio
    Bagni, Oreste
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (11) : E692 - E695
  • [25] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Rahul V. Parghane
    Sandip Basu
    Journal of Nuclear Cardiology, 2020, 27 : 340 - 341
  • [26] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [27] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Review of Treatment Workflow and Challenging Clinical Scenarios
    Abiodun-Ojo, Olayinka
    Shin, Muheon
    Chopra, Jigyasa
    Muzahir, Saima
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [28] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Basu, Sandip
    JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (01) : 340 - 341
  • [29] Data collection procedures for bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE on neuroendocrine tumors
    Frederiksen, M. H. B.
    Klausen, T. L.
    de Nijs, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S631 - S631
  • [30] 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Hofman, Michael S.
    Michael, Michael
    Hicks, Rodney J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1390 - 1391
12345